

## **Folate Receptor-mediated Enhanced and Specific Delivery of Far-red Light-activatable Prodrugs of Combretastatin A-4 to FR-positive Tumor**

Gregory Nkepang<sup>†</sup>, Moses Bio<sup>†</sup>, Pallavi Rajaputra<sup>†</sup>, Samuel Awuah<sup>†</sup>, and Youngjae You<sup>†,‡,\*</sup>.

<sup>†</sup>Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, United States

<sup>‡</sup>Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States


Corresponding author: Youngjae You, phone: 1-405-271-6593, ext. 47473; fax: 1-405-271-7505; email: [youngjae-you@ouhsc.edu](mailto:youngjae-you@ouhsc.edu)

**Supplementary Information (SI)**


## Table of Contents

<b>Scheme S1.</b> Preparation of compound <b>13</b> .....	1
<b>Scheme S2.</b> Synthesis of compounds <b>15</b> and <b>17</b> .....	2
<b>Figure S1.</b> Absorption spectra of prodrugs <b>1-5</b> .....	3
<b>Figure S2.</b> Body weight changes during the antitumor study.....	4
<b>Figure S3.</b> Dark toxicity of prodrugs <b>1-5</b> .....	4
<b>Figure S4.</b> Confocal microscopic images of colon 26 cells with prodrugs <b>4</b> and <b>5</b> .....	5
<b>Figures S5, S6, &amp; S7.</b> <sup>1</sup> H-NMR, peak assignment, and HRMS of compound <b>7</b> .....	6
<b>Figures S8, S9, &amp; S10.</b> <sup>1</sup> H, <sup>13</sup> C-NMR, and HRMS of compound <b>8</b> .....	8
<b>Figures S11, S12, &amp; S13.</b> <sup>1</sup> H, <sup>13</sup> C-NMR, and HRMS of compound <b>9</b> .....	11
<b>Figures S14 &amp; S15.</b> <sup>1</sup> H-NMR and LRMS of compound <b>15</b> .....	12
<b>Figures S16 &amp; S17.</b> <sup>1</sup> H-NMR and LRMS of compound <b>17</b> .....	13
<b>Figures S18, S19, S20, S21, &amp; S22.</b> <sup>1</sup> H-NMR, peak assignment, <sup>13</sup> C-NMR, HRMS, and HPLC chromatogram of prodrug <b>1</b> .....	14
<b>Figures S23, S24, S25, &amp; S26.</b> <sup>1</sup> H-NMR, <sup>13</sup> C-NMR, HRMS, and HPLC chromatogram of prodrug <b>2</b> .....	17
<b>Figures S27, S28 &amp; S29.</b> <sup>1</sup> H-NMR, HRMS, and HPLC chromatogram of prodrug <b>3</b> .....	19
<b>Figures S30, S31, &amp; S32.</b> <sup>1</sup> H-NMR, peak assignment, peak integrations of prodrug <b>4</b> .....	21
<b>Figures S33, S34, &amp; S35.</b> <sup>1</sup> H-NMR, HRMS, and HPLC chromatogram of prodrug <b>5</b> .....	24
<b>Figure S36.</b> Photographic images of mice treated with prodrugs <b>4</b> and <b>5</b> .....	26
<b>Figure S37.</b> Additional optical images of mice treated with prodrugs <b>1-5</b> .....	27







**Scheme S2.** Synthesis for compounds **15** and **17**. (a) Diamine **14** (1 eq.), Boc<sub>2</sub>O (1 eq.) TEA (3 eq.), anhydrous MeOH (9.31 mL), reflux, 24 h, 72% yield. (b) sonicated FA (1 eq) in DCC (6.7 eq), 30 min, DMF/Pyridine (5:1 v/v), **15** (1 eq.), rt, 36 h precipitate in cold Et<sub>2</sub>O/Acetone (3:1 v/v), 73% yield. C) TFA, rt, 4 h.




**Figure S1.** Absorption spectra of prodrugs (A) prodrug 1, (B) prodrug 2, (C) prodrug 3, (D) prodrug 4, and (E) prodrug 5 in DMF at different concentrations. The inset of each spectrum plots the Q-band absorbance vs. concentration of the conjugate.




**Figure S2.** Body weight changes during the antitumor efficacy study. Changes are presented as an average of all three mice in each group. SD values were not added, for clarity.




**Figure S3.** Dark toxicity of prodrugs 1-5.



**Figure S4.** Confocal microscopy images of colon 26 cells incubated for 1 h 15 min with (A) prodrug 4 and (B) prodrug 5 at the concentration of 20  $\mu$ M (excitation at 633 nm and emission at 640 – 700 nm).




**Figure S5:**  $^1\text{H}$ -NMR of compound 7.



**Figure S6:** Peak Assignment on  $^1\text{H}$ -NMR of compound 7.





**Figure S7.** HRMS (ESI) of compound **7**. Calculated for  $\text{C}_{65}\text{H}_{63}\text{N}_{13}\text{O}_8\text{Si}$   $[\text{M} + \text{H}]^+$ : 1167.2661 and  $\text{C}_{65}\text{H}_{61}\text{N}_{12}\text{O}_8\text{SiNa}$   $[\text{M} + \text{Na}]^+$ : 1189.4481, found: m/z 1167.4665 and 1189.4479.




Figure S8.  $^1\text{H}$ -NMR of compound 8.






Figure S9.  $^{13}\text{C}$ -NMR of compound 8.




**Figure S10.** HRMS-ESI of compound **8**. Calculated for  $C_{71}H_{69}N_{12}O_9Si$   $[M+H]^+$ : 1261.5090 and  $C_{71}H_{68}N_{12}O_9SiNa$   $[M+Na]^+$ : 1283.4899, found: 1261.5077 and 1283.4891.







**Figure S13.** HRMS-ESI of compound **9**. Calculated for  $C_{69}H_{66}N_{12}O_{12}Si$ :  $[M + H]^+$ : 1283.4771 found m/z 1283.4781.




**Figure S14.**  $^1\text{H}$ -NMR of compound **15**.




**Figure S15.** LRMS (ESI) of compound **15**. Calculated for  $\text{C}_{45}\text{H}_{93}\text{N}_2\text{O}_{21}$   $[\text{M} + \text{H}]^+$ : 997.7, found:  $m/z$  997.7.




**Figure S16.**  $^1\text{H}$ -NMR of compound 17.




**Figure S17.** LRMS (ion trap) of 17. Calculated  $\text{C}_{64}\text{H}_{110}\text{N}_9\text{O}_{26}$   $[\text{M}+\text{H}]^+$ : 1420.7, found:  $M/z$  1420.7.









**Figure S19.** Assignment of peaks to the  $^1\text{H}$ -NMR of prodrug **1**.



**Figure S20.**  $^{13}\text{C}$ -NMR of prodrug **1**.




**Figure S21.** HRMS (ESI) of prodrug **1**. Calculated for  $C_{84}H_{59}N_{20}O_{13}Si$   $[M + H]^+$ : 1590.5952, found: 1590.5938.




Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		5.940	47965.398	1001771.625	96.2589
2		6.848	6831.381	38933.301	3.7411
Total			54796.779	1040704.926	100.0000

**Figure S22.** HPLC chromatogram of prodrug **1**. Retention time 5.9 min. Method: Isocratic, solvent system: 50% ACN 50%  $H_2O$ , flow rate 0.5 mL/min, Detection at 254 nm, and purity: 96%.







**Figure S25.** HRMS-ESI of prodrug **2**. Calculated for  $[\text{C}_9\text{H}_{99}\text{N}_{23}\text{O}_{16}\text{SiNa}_2]^{+2}$   $[\text{M}+2\text{Na}]^{+2}$ : 951.8602, found: 951.9423.



Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		3.348	355075.969	5549544.500	97.0861
2		3.932	16456.631	129944.125	2.2733
3		4.073	11506.306	36620.211	0.6406
Total			383038.905	5716108.836	100.0000


**Figure S26.** HPLC chromatogram of prodrug **2**. Retention time 3.4 min. Method: Isocratic, solvent system: 50% ACN 50%  $\text{H}_2\text{O}$ , flow rate 0.5 mL/min, Detection at 254 nm, and purity: 97%.






Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		3.465	5709.000	14762.400	0.1774
2		4.782	306122.813	7286394.000	87.5451
3		6.157	52182.656	622986.875	7.4851
4		6.273	47067.473	398874.313	4.7924
Total			411081.941	8323017.588	100.0000

**Figure S29.** HPLC chromatogram of prodrug **3**. Retention time 4.74 min. Method: Isocratic, solvent system: 60% ACN 40% H<sub>2</sub>O, flow rate 0.5 mL/min, Detection at 254 nm, and purity: 87%.




**Figure S30:**  $^1\text{H}$ -NMR of prodrug 4.




**Figure S31.** Assignment of peaks on the  $^1\text{H}$ -NMR of (i)  $\text{NH}_2\text{-PEG}_{45}\text{-FA}$  and (ii) prodrug **4**. The peaks at 2.5, 3.05, and 5.39 ppm were from the following solvents: DMSO,  $\text{H}_2\text{O}$ , and DCM, respectively.







**Figure S32:** The integration of the  $^1\text{H}$ -NMR peaks at 8.63 ppm (H-20) and 4.33 (H-8) ppm of FA and aminoacrylate bond respectively with respect to the peaks at 9.63 ppm (H-1', 4', 8H) and 8.39 ppm (H-2', 3', 8H) of the phthalocyanine (Pc) core. Based peaks indicate an almost 1:1 ratio (0.913 vs. 0.995) of the conjugated FA and CA4, thereby demonstrating a complete reaction between compounds **9** and **10** to produce the prodrug **4**. NB. These are the only two isolated peaks from compounds **9** and **10** that could be integrated with some degree of certainty. The rest of the peaks overlap with each other.



**Figure S33.** <sup>1</sup>H-NMR of Prodrug **5**. The peak at 5.30 ppm is the DCM peak.




**Figure S34.** HRMS (TOF) of prodrug **5**. HRMS (ESI):  $m/z=2261.0779$  calcd for  $[C_{114}H_{158}N_{14}O_{32}Si]^{+2} [M+2H]^{+2}$ : 1131.5468 (81.1%) and 1132.0462 (100%), found: 1131.5644 (81.1%) and 1132.0611(100%).




Results					
Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		6.440	82370.523	2283782.500	100.0000
Total			82370.523	2283782.500	100.0000

**Figure S35.** HPLC chromatogram of prodrug **5**. Retention time 6.44 min. Method: Isocratic, solvent system: 60% ACN 40% H<sub>2</sub>O, flow rate 0.5 mL/min.



**Figure S36.** Photographic images of the other two groups of mice (3 mice per group) treated with prodrug (none, 4, or 5 at 2  $\mu\text{mol/kg}$ ) with illumination (690 nm laser, 12 mm diameter circular beam, 100  $\text{mW/cm}^2$ , 30 min,) 7 h post IV administration of the prodrug: (i) day 0 before illumination, (ii) day 1, (iii) day 6, and (iv) day 15 post-illumination.



**Figure S37.** Additional data set of time-dependent preclinical fluorescence images of prodrugs 1-5 (Fig. 5A). Images of Balb/c mice bearing SC colon 26 tumors were taken before and at 0.25, 1, 3, 7, 9, 24, 48, and 72 h post IV injection of the prodrugs (2  $\mu$ mol/kg).